Metastatic Hormone-Sensitive Prostate Cancer

Dr. Kelly Fitzgerald explains current standards of care for metastatic hormone-sensitive prostate cancer, focusing on treatment strategies shaped by both clinical trial data and emerging imaging technologies. She defines key terms such as poly- and oligometastatic disease and outlines how newer imaging methods like PSMA PET scans are reshaping diagnosis. She describes the shift from traditional androgen deprivation therapy (ADT) to intensified ADT, where additional agents—such as chemotherapy or novel hormone therapies—are shown to improve survival. Fitzgerald also reviews ongoing questions around triplet therapy and the potential benefits of local treatments like radiation. She highlights the importance of patient-specific factors and the evolving definitions that influence treatment decisions in this complex disease landscape. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40809]

There are no comments yet.

Please log in to write the first comment.